These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 29780361)

  • 41. Lytic activity of phages against bacterial pathogens infecting diabetic foot ulcers.
    Kifelew LG; Warner MS; Morales S; Gordon DL; Thomas N; Mitchell JG; Speck PG
    Sci Rep; 2024 Feb; 14(1):3515. PubMed ID: 38347019
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Use of Phage Cocktail BFC 1.10 in Combination With Ceftazidime-Avibactam in the Treatment of Multidrug-Resistant
    Racenis K; Rezevska D; Madelane M; Lavrinovics E; Djebara S; Petersons A; Kroica J
    Front Med (Lausanne); 2022; 9():851310. PubMed ID: 35547216
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Directed in Vitro Evolution of Therapeutic Bacteriophages: The Appelmans Protocol.
    Burrowes BH; Molineux IJ; Fralick JA
    Viruses; 2019 Mar; 11(3):. PubMed ID: 30862096
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The susceptibility of Pseudomonas aeruginosa strains from cystic fibrosis patients to bacteriophages.
    Essoh C; Blouin Y; Loukou G; Cablanmian A; Lathro S; Kutter E; Thien HV; Vergnaud G; Pourcel C
    PLoS One; 2013; 8(4):e60575. PubMed ID: 23637754
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effectiveness and role of phages in the disruption and inactivation of clinical P. aeruginosa biofilms.
    Namonyo S; Weynberg KD; Guo J; Carvalho G
    Environ Res; 2023 Oct; 234():116586. PubMed ID: 37423363
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of expanded host range phage active on biofilms of multi-drug resistant
    Mapes AC; Trautner BW; Liao KS; Ramig RF
    Bacteriophage; 2016; 6(1):e1096995. PubMed ID: 27144083
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Therapeutic effect and anti-biofilm ability assessment of a novel phage, phiPA1-3, against carbapenem-resistant Pseudomonas aeruginosa.
    Tsai YC; Lee YP; Lin NT; Yang HH; Teh SH; Lin LC
    Virus Res; 2023 Oct; 335():199178. PubMed ID: 37490958
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Isolation and Characterization of Lytic Bacteriophage Against Multi-drug Resistant Pseudomonas aeruginosa.
    Maharjan A; Nepal R; Dhungana G; Parajuli A; Regmi M; Upadhyaya E; Mandal D; Shrestha M; Pradhan P; Manandhar KD; Malla R
    J Nepal Health Res Counc; 2022 Mar; 19(4):717-724. PubMed ID: 35615828
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization and
    Harada LK; Silva EC; Rossi FP; Cieza B; Oliveira TJ; Pereira C; Tomazetto G; Silva BB; Squina FM; Vila MM; Setubal JC; Ha T; da Silva AM; Balcão VM
    Future Microbiol; 2022 Jan; 17():111-141. PubMed ID: 34989245
    [No Abstract]   [Full Text] [Related]  

  • 50. Differential Effect of Newly Isolated Phages Belonging to PB1-Like, phiKZ-Like and LUZ24-Like Viruses against Multi-Drug Resistant Pseudomonas aeruginosa under Varying Growth Conditions.
    Latz S; Krüttgen A; Häfner H; Buhl EM; Ritter K; Horz HP
    Viruses; 2017 Oct; 9(11):. PubMed ID: 29077053
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Selection and characterization of bacteriophages specific to
    Sriprasong P; Imklin N; Nasanit R
    Vet World; 2022 Dec; 15(12):2856-2869. PubMed ID: 36718326
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Engineered Superinfective Pf Phage Prevents Dissemination of Pseudomonas aeruginosa in a Mouse Burn Model.
    Prokopczuk FI; Im H; Campos-Gomez J; Orihuela CJ; Martínez E
    mBio; 2023 Jun; 14(3):e0047223. PubMed ID: 37039641
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of Lytic Phage Cocktails on
    Kifelew LG; Warner MS; Morales S; Thomas N; Gordon DL; Mitchell JG; Speck PG
    Viruses; 2020 May; 12(5):. PubMed ID: 32443619
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Isolation and characterization of lytic bacteriophages from sewage at an egyptian tertiary care hospital against methicillin-resistant
    Samir S; El-Far A; Okasha H; Mahdy R; Samir F; Nasr S
    Saudi J Biol Sci; 2022 May; 29(5):3097-3106. PubMed ID: 35360502
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
    Ciofu O
    APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens.
    Viertel TM; Ritter K; Horz HP
    J Antimicrob Chemother; 2014 Sep; 69(9):2326-36. PubMed ID: 24872344
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bacteriophage Treatment before Chemical Disinfection Can Enhance Removal of Plastic-Surface-Associated Pseudomonas aeruginosa.
    Stachler E; Kull A; Julian TR
    Appl Environ Microbiol; 2021 Sep; 87(20):e0098021. PubMed ID: 34347517
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biofilm differentiation and dispersal in mucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis.
    Kirov SM; Webb JS; O'May CY; Reid DW; Woo JKK; Rice SA; Kjelleberg S
    Microbiology (Reading); 2007 Oct; 153(Pt 10):3264-3274. PubMed ID: 17906126
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Considerations for Phage Therapy Against
    Senhaji-Kacha A; Esteban J; Garcia-Quintanilla M
    Front Microbiol; 2020; 11():609017. PubMed ID: 33537013
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhaled Bacteriophage Therapy for Multi-Drug Resistant
    Winzig F; Gandhi S; Lee A; Würstle S; Stanley GL; Capuano I; Neuringer I; Koff JL; Turner PE; Chan BK
    Yale J Biol Med; 2022 Dec; 95(4):413-427. PubMed ID: 36568830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.